Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tiotropium · Spiriva Handihaler, Spiriva Respimat

Small molecule · Antagonist of Muscarinic acetylcholine receptor M3 (CHRM3) · developed by Boehringer Ingelheim

Approved FDA, Jan 2004

What is Tiotropium?

Tiotropium is a long-acting antimuscarinic agent that competitively and reversibly antagonizes M3 muscarinic receptors on airway smooth muscle, producing bronchodilation. It is used in maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease and of asthma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Spiriva Handihaler, Spiriva Respimat, Spiriva
Drug type
Small molecule
Targets
Muscarinic acetylcholine receptor M3 (CHRM3)
Mechanism
Antagonist of Muscarinic acetylcholine receptor M3 (CHRM3)
Pathways
bronchoconstriction
Therapy area
Respiratory
Developer
Boehringer Ingelheim
In trials of
VTRS
FDA status
Approved as Spiriva Handihaler, Spiriva Respimat (January 30, 2004), NDA021395 · FDA label
UNII
0EB439235F

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 17, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Chronic Obstructive Pulmonary Disease

Other drugs acting on CHRM3

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.